| Not Yet Recruiting | Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress NCT06999109 | Duke University | N/A |
| Not Yet Recruiting | Omega-3 Supplementation in Systemic Lupus Erythematosus NCT07393399 | University of Sao Paulo | N/A |
| Not Yet Recruiting | Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus NCT07381465 | Chinese SLE Treatment And Research Group | Phase 4 |
| Recruiting | NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care NCT07424261 | AstraZeneca | — |
| Recruiting | A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus NCT07438496 | Janssen Research & Development, LLC | Phase 3 |
| Not Yet Recruiting | Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting NCT07349667 | Aarhus University Hospital | N/A |
| Recruiting | A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regu NCT07201129 | Viatris Innovation GmbH | Phase 3 |
| Recruiting | Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. NCT07330245 | AstraZeneca | — |
| Completed | Prognostic Factors for Fatigue in Patients With Systemic Lupus Erythematosus NCT07123220 | Investigación en Hemofilia y Fisioterapia | — |
| Recruiting | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE NCT07015983 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 2 |
| Recruiting | Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus NCT06881290 | Chinese SLE Treatment And Research Group | Phase 1 |
| Recruiting | A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE NCT06897930 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Dise NCT06842316 | Centre Hospitalier Régional d'Orléans | — |
| Not Yet Recruiting | Physical Activity in Patients With Systemic Lupus Erythematosus NCT06919250 | University of Oviedo | — |
| Recruiting | Dose Response of Exercise for Arthritis Management NCT06880653 | University of South Carolina | N/A |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease NCT06925542 | CRISPR Therapeutics | Phase 1 |
| Enrolling By Invitation | The Effect of Clinical Pilates Training on Fatigue, Emotional State, Functional Capacity, Sleep and Quality of NCT07394361 | Emir İbrahim IŞIK | N/A |
| Recruiting | Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus NCT06673043 | AstraZeneca | — |
| Recruiting | Chinese Rheumatism Biobank(CRB) NCT06887517 | Chinese SLE Treatment And Research Group | — |
| Not Yet Recruiting | Sirolimus Treatment Of Patients With SLE NCT04736953 | State University of New York - Upstate Medical University | Phase 2 |
| Enrolling By Invitation | Engagement in CHildhood-Onset Systemic Lupus NCT05693571 | Montefiore Medical Center | N/A |
| Recruiting | Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases NCT06685042 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 1 / Phase 2 |
| Recruiting | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis NCT06581198 | Novartis Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases NCT06567080 | RenJi Hospital | Phase 1 |
| Enrolling By Invitation | Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus NCT06475742 | Viatris Innovation GmbH | Phase 3 |
| Not Yet Recruiting | A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus NCT06373991 | EdiGene Inc. | Phase 1 |
| Recruiting | Brief Pain Exposure Therapy (BPET) For Nociplastic Pain NCT06208514 | University of Michigan | N/A |
| Recruiting | Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimm NCT07249060 | Hospital Universitario Araba | — |
| Recruiting | Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and NCT05845593 | Ampel BioSolutions, LLC | — |
| Unknown | JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus NCT05967520 | Jemincare | Phase 2 |
| Unknown | Pulmonary Disease Among Patients With Systemic Lupus Erythematosus NCT06087523 | Odense University Hospital | — |
| Completed | Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism NCT05961267 | University Hospital, Bordeaux | — |
| Terminated | A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms. NCT05879718 | Pfizer | Phase 2 |
| Active Not Recruiting | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Er NCT05672576 | Viatris Innovation GmbH | Phase 3 |
| Unknown | Microvascular Ocular Changes of Systemic Lupus Erythematous NCT05863689 | Universidade do Porto | — |
| Completed | Validation of Patient E-tool to Measure Systemic Lupus Activity NCT05763225 | Association Francaise du Lupus et Autres Maladies Auto-immunes (AFL+) | — |
| Active Not Recruiting | Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial) NCT05590390 | Azienda Ospedaliera Universitaria Integrata Verona | — |
| Recruiting | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus NCT05648500 | Viatris Innovation GmbH | Phase 3 |
| Recruiting | Effects of High-intensity Interval Training in Patients With Systemic Lupus Erythematosus NCT06166199 | Karolinska Institutet | N/A |
| Unknown | Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular NCT05636670 | Nanfang Hospital, Southern Medical University | — |
| Unknown | Efficacy and Safety of Telitacicept in Early SLE NCT05899907 | Peking Union Medical College Hospital | Phase 4 |
| Unknown | Optimization of Glucocorticoid Taper Strategies for SLE-ITP NCT05506033 | Fujian Medical University Union Hospital | N/A |
| Completed | Occupational and Environmental Causes of Autoimmune Diseases NCT07000903 | Université Catholique de Louvain | N/A |
| Completed | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Part NCT05278663 | Eisai Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Phone-Based Based Walk With Ease Program for Adults With Arthritis NCT05289544 | University of South Carolina | N/A |
| Terminated | Mediterranean vs. High-Fermented-Food Diet Adherence on Inflammation in Lupus NCT05379725 | University of Florida | N/A |
| Terminated | Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE) NCT05203419 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322) NCT05193591 | University Hospital, Grenoble | — |
| Active Not Recruiting | Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE NCT06015230 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Mast Cells Are Involved in the Mechanism of NPSLE Epilepsy NCT05607368 | Nanfang Hospital, Southern Medical University | — |
| Active Not Recruiting | SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS) NCT05141201 | AstraZeneca | — |
| Recruiting | Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases NCT06316791 | Juventas Cell Therapy Ltd. | EARLY_Phase 1 |
| Unknown | Effects of an Intervention With EVOO and Physical Activity in Patients With Systemic Lupus Erythematosus NCT05261529 | Universidad de Granada | N/A |
| Completed | Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythemato NCT05326841 | Dr Cipto Mangunkusumo General Hospital | Phase 3 |
| Completed | Belimumab In Early Systemic Lupus Erythematosus NCT04956484 | Peking Union Medical College Hospital | Phase 4 |
| Completed | Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial NCT04776161 | Brigham and Women's Hospital | N/A |
| Active Not Recruiting | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of NCT04961567 | Biogen | Phase 3 |
| Completed | Study of VIB7734 for the Treatment of Moderate to Severely Active SLE NCT04925934 | Amgen | Phase 2 |
| Active Not Recruiting | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of NCT04895241 | Biogen | Phase 3 |
| Recruiting | Trial of Belimumab in Early Lupus NCT03543839 | Northwell Health | Phase 4 |
| Withdrawn | A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus NCT04060888 | Janssen Research & Development, LLC | Phase 3 |
| Unknown | Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals NCT04449653 | Progentec Diagnostics, Inc. | — |
| Withdrawn | A Pilot Study to Explore the Role of Gut Flora in Lupus NCT04213690 | ProgenaBiome | — |
| Unknown | Contemplation-Based Intervention and Health Outcomes RCT in Lupus Patients NCT04032496 | University of Toronto | N/A |
| Completed | Effect of Insoles in Patients With Systemic Lupus Erythematosus NCT04098055 | University of Seville | N/A |
| Completed | A Study of LY3361237 in Participants With Systemic Lupus Erythematosus NCT03933943 | Eli Lilly and Company | Phase 1 |
| Completed | Internet-Based Pain Coping Skills Training for Patients With Lupus NCT03933839 | University of North Carolina, Chapel Hill | N/A |
| Active Not Recruiting | Lupus Intervention for Fatigue Trial NCT02653287 | Northwestern University | N/A |
| Completed | Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus NCT03896373 | University Hospital, Tours | — |
| Unknown | Mesenchymal Stromal Cells (MSC´s) in Renal Lupus NCT03917797 | Universidad de los Andes, Chile | Phase 2 |
| Withdrawn | BI 705564 in Patients With Systemic Lupus Erythematosus (SLE) NCT03771885 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination Wit NCT03724916 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | Synergetic B-cell Immunomodulation in SLE - 2nd Study. NCT03747159 | Leiden University Medical Center | Phase 3 |
| Active Not Recruiting | Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus NCT03527472 | Vanderbilt University Medical Center | Phase 2 |
| Completed | Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus NCT03312335 | Onur Boyman, MD | Phase 2 |
| Completed | Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques NCT03687138 | Natalia A. Rivera García | — |
| Unknown | Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Ery NCT03746197 | National Jewish Health | N/A |
| Completed | Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treat NCT03187743 | Assistance Publique - Hôpitaux de Paris | N/A |
| Terminated | A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus NCT03517722 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | Meir Medical Center Rheumatologic Biobank NCT03473912 | Meir Medical Center | — |
| Completed | Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythem NCT03504540 | Fondation Ophtalmologique Adolphe de Rothschild | — |
| Completed | Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With System NCT03427151 | ImmuPharma | Phase 3 |
| Terminated | An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus NCT03407482 | Genentech, Inc. | Phase 2 |
| Unknown | Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain NCT02822989 | Northwell Health | N/A |
| Completed | A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE NCT03098823 | Ampel BioSolutions, LLC | Phase 4 |
| Completed | Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases NCT03248518 | University of Aberdeen | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus NCT03161483 | Celgene | Phase 2 |
| Completed | Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus NCT03142711 | Lupus Research Alliance | — |
| Terminated | Acupressure for Fatigue in Systemic Lupus Erythematosus NCT03200548 | Suzanna Zick | N/A |
| Completed | Improving the Assessment of SLE Disease Activity NCT03144063 | University Health Network, Toronto | — |
| Withdrawn | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With System NCT02920424 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Pilot Study to Investigate Contemplative Intervention in Lupus Patients NCT03103243 | University of Virginia | N/A |
| Unknown | Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization NCT03142412 | DxTerity Diagnostics | — |
| Unknown | Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous NCT03042260 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 4 |
| Completed | Women Empowered to Live With Lupus Study NCT02988661 | Emory University | N/A |
| Completed | Acthar Gel for Active Systemic Lupus Erythematosus (SLE) NCT02953821 | Mallinckrodt | Phase 4 |
| Completed | Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud NCT03027674 | Pontificia Universidad Catolica de Chile | EARLY_Phase 1 |
| Completed | Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi) NCT02732470 | University Hospital, Limoges | N/A |
| Terminated | TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment NCT02711813 | Theramab LLC | Phase 2 |
| Unknown | The Role of Lipids in Immune Cell Function in SLE Patients NCT04361734 | University College, London | — |
| Completed | MSC2364447C Phase 1b in Systemic Lupus Erythematosus NCT02537028 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Completed | A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus NCT02349061 | Janssen Research & Development, LLC | Phase 2 |
| Completed | The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis NCT02655640 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | Effect of Green Tea on Treatment of Lupus NCT02875691 | Ahvaz Jundishapur University of Medical Sciences | Phase 2 |
| Terminated | Autologous Polyclonal Tregs for Lupus NCT02428309 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus NCT02437890 | Ablynx, a Sanofi company | Phase 2 |
| Completed | A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Saf NCT02504645 | ImmuPharma | Phase 3 |
| Terminated | Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS NCT02070978 | EMD Serono | Phase 2 |
| Completed | A Complex Contraception Registry NCT02219269 | University of California, San Diego | — |
| Completed | Systemic Lupus Erythematous and Heart Conduction Disorders NCT02162992 | Germans Trias i Pujol Hospital | — |
| Completed | Synergetic B-cell Immodulation in SLE NCT02284984 | Leiden University Medical Center | Phase 2 |
| Terminated | A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus NCT02041091 | Eli Lilly and Company | Phase 3 |
| Completed | Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus NCT01972568 | EMD Serono | Phase 2 |
| Completed | A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy V NCT02034344 | Janssen Research & Development, LLC | — |
| Completed | Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients NCT02922114 | Centre Hospitalier Régional d'Orléans | N/A |
| Completed | Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics NCT01838694 | Invion, Inc. | Phase 1 / Phase 2 |
| Unknown | Employment and Arthritis: Making it Work NCT01852851 | University of British Columbia | N/A |
| Completed | A Non-drug Study Profiling Cutaneous Lupus NCT01923415 | Janssen Research & Development, LLC | — |
| Completed | An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults NCT01753193 | MedImmune LLC | Phase 2 |
| Completed | Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus NCT01764594 | UCB Pharma | Phase 1 |
| Completed | Anti-ficolin-2 Autoantibodies in Lupus Nephritis NCT03063281 | University Hospital, Grenoble | — |
| Completed | Anti-ficolin-3 Autoantibodies in Lupus Nephritis NCT02625831 | University Hospital, Grenoble | — |
| Enrolling By Invitation | Comparative Autoantibody and Immunologic Cell Marker Study NCT02422875 | Emory University | — |
| Completed | Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Eryt NCT01597050 | Rigel Pharmaceuticals | Phase 2 |
| Completed | Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients NCT04266860 | Qure Healthcare, LLC | N/A |
| Completed | Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis NCT01582880 | Joseph B. Ciolino, MD | Phase 1 / Phase 2 |
| Completed | Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematos NCT01405196 | Pfizer | Phase 2 |
| Unknown | Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus NCT01471301 | Federal University of São Paulo | — |
| Terminated | GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases NCT01257802 | Joseph Mccune | Phase 3 |
| Completed | Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteop NCT02799173 | Centre Hospitalier Universitaire, Amiens | N/A |
| Completed | Evaluation of the Influence of Food Regimen on Oshadi D Absorption NCT01327352 | Oshadi Drug Administration | N/A |
| Terminated | CMR-Lupus Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography NCT03488654 | University Hospital, Basel, Switzerland | — |
| Completed | Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Tr NCT01060410 | Sun Yat-sen University | — |
| Terminated | A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus NCT01127321 | MedImmune LLC | Phase 1 |
| Completed | Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) NCT01093911 | UCB Pharma | Phase 1 |
| Withdrawn | Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE NCT01702038 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus NCT00714116 | Pfizer | Phase 1 |
| Completed | Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis NCT00774852 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus NCT00657189 | MedImmune LLC | Phase 2 |
| Completed | Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus NCT00611663 | Assistance Publique - Hôpitaux de Paris | Phase 2 / Phase 3 |
| Completed | Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) NCT00624338 | EMD Serono | Phase 2 / Phase 3 |
| Completed | A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Syst NCT01702740 | Centocor Research & Development, Inc. | Phase 1 |
| Completed | Phase Ib Study of SC Milatuzumab in SLE NCT01845740 | Gilead Sciences | Phase 1 |
| Unknown | European Society of Cutaneous Lupus Erythematosus (EUSCLE) NCT00420121 | European Society of Cutaneous Lupus Erythematosus e.V. | — |
| Completed | Sirolimus for Autoimmune Disease of Blood Cells NCT00392951 | Children's Hospital of Philadelphia | Phase 1 / Phase 2 |
| Terminated | TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) NCT00368264 | Medical University of Vienna | Phase 2 / Phase 3 |
| Terminated | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus NCT00381810 | Genentech, Inc. | Phase 3 |
| Completed | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus NCT00137969 | Genentech, Inc. | Phase 2 / Phase 3 |
| Terminated | Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) NCT00113971 | UCB Pharma | Phase 2 |
| Terminated | Study of LJP 394 in Lupus Patients With History of Renal Disease NCT00089804 | La Jolla Pharmaceutical Company | Phase 3 |
| Completed | Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) NCT00094380 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Terminated | Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus NCT00325741 | Stanford University | Phase 1 |
| Completed | Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus NCT00076752 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis NCT00125307 | Chinese University of Hong Kong | Phase 4 |
| Completed | Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) NCT00071487 | Human Genome Sciences Inc. | Phase 2 |
| Completed | Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) NCT00065806 | Laura Schanberg | Phase 3 |
| Terminated | Physical Therapy for Systemic Lupus Erythematosus (SLE) NCT00152555 | University of Chicago | N/A |
| Completed | Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome NCT00025818 | Allergan | Phase 3 |
| Completed | Anti-CD20 in Systemic Lupus Erythematosus NCT00036491 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome NCT00391924 | UMC Utrecht | Phase 2 |
| Completed | Analyzing the Association of Gene Variants With Increased Risk of Coronary Heart Disease in Women With Systemi NCT00563082 | University of Pittsburgh | — |
| Completed | High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide NCT00005778 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 3 |
| Completed | Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythema NCT00582465 | University of California, San Francisco | — |
| Completed | Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus NCT00004643 | National Center for Research Resources (NCRR) | Phase 2 |
| Completed | Lupus Cohort--Thrombotic Events and Coronary Artery Disease NCT00005436 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Unknown | Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus NCT00008749 | National Center for Research Resources (NCRR) | — |